MarketCapExport financials
Silk Road Medical, Inc (SILK)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Silk Road Medical, Inc Income Statement 2023-2011 | SILK
Brief overview of financial performance at Silk Road Medical, Inc
The overview follows changes across a five-year period. According to figures from Silk Road Medical, Inc, revenue changed from 34.6 million dollars to 177 million dollars over five years. Overall revenue changed by +412.6%, equal to an annualized rate of about 38.7%. The annual growth rate indicates an exceptionally strong top-line trend.
Gross profit changed from 23.7 million dollars to 127 million dollars (+436.6%). Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. Comparing the endpoints gives gross margins of 68.5% and 71.7%. The business retained more gross profit from each unit of revenue.
Over the period, EBITDA shifted from −20.9 million dollars to −56.6 million dollars, a change of −171%. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin was −60.4% at the start and −31.9% at the end. The business generated more EBITDA from each unit of revenue.
Comparing the endpoints shows a move from −$37.6 million to −$55.7 million. Profitability deteriorated further over the five years.
Conclusion
The results present an uneven picture without one dominant signal. The financial profile benefits from higher operating efficiency, a larger revenue base and improving gross profitability. The main areas of concern are lower net income and limited operating profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Silk Road Medical, Inc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
683 M | 1.9 B | 1.48 B | 2.08 B | 927 M | - | 36.1 M | - | - | - | - | - | - |
Shares |
38.8 M | 35.8 M | 34.6 M | 33 M | 23 M | 961 K | 24.1 M | - | - | - | - | - | - |
Historical Prices |
17.6 | 53 | 42.6 | 63 | 40.4 | - | - | - | - | - | - | - | - |
Net Income |
-55.7 M | -55 M | -49.8 M | -47.4 M | -52.4 M | -37.6 M | -19.4 M | - | - | - | - | - | - |
Revenue |
177 M | 139 M | 101 M | 75.2 M | 63.4 M | 34.6 M | 14.3 M | - | - | - | - | - | - |
Cost of Revenue |
50 M | 37.9 M | 25.4 M | 21.3 M | 15.9 M | 10.9 M | - | - | - | - | - | - | - |
Gross Profit |
127 M | 101 M | 76 M | 53.9 M | 47.4 M | 23.7 M | 9.13 M | - | - | - | - | - | - |
Operating Income |
-59.3 M | -52 M | -47.5 M | -42.9 M | -28.1 M | -21.4 M | - | - | - | - | - | - | - |
Interest Expense |
6.87 M | 5.1 M | 2.52 M | 4.41 M | 4.95 M | 4.36 M | - | - | - | - | - | - | - |
EBITDA |
-56.6 M | -49.9 M | -46.4 M | -42.1 M | -27.4 M | -20.9 M | -18.2 M | - | - | - | - | - | - |
Operating Expenses |
186 M | 153 M | 123 M | 96.8 M | 75.5 M | 45.1 M | 27.5 M | - | - | - | - | - | - |
General and Administrative Expenses |
145 M | 116 M | 96.4 M | 75.5 M | 63.2 M | 34.8 M | 20.3 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Silk Road Medical, Inc
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
39.6 M | 39.3 M | 39.2 M | 38.9 M | 38.8 M | 38.5 M | 38.4 M | 35.3 M | 35.1 M | 35 M | 35 M | 34.7 M | 34.5 M | 34.3 M | 34.2 M | 33.8 M | 32.7 M | 31.3 M | 31.3 M | 30.8 M | 28.5 M | 1.2 M | 1.14 M | 1.05 M | 938 K | 739 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-16.6 M | -14.1 M | - | -12.8 M | -13.5 M | -16.5 M | - | -10.3 M | -15.4 M | -16.7 M | - | -13.9 M | -10.5 M | -10.7 M | -16.8 M | -10.3 M | -10.4 M | -9.94 M | -8.29 M | -8.01 M | -12 M | -24.2 M | -15.6 M | -8.95 M | -7.65 M | -5.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
51.2 M | 48.5 M | - | 44.4 M | 45.3 M | 40.1 M | - | 37.4 M | 33.2 M | 28 M | - | 24.7 M | 26.5 M | 22.1 M | 21.1 M | 20.1 M | 15.1 M | 18.9 M | 18.6 M | 17 M | 14.9 M | 12.8 M | 11.5 M | 9.61 M | 7.77 M | 5.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
12.7 M | 12 M | - | 12 M | 13 M | 12.5 M | - | 9.31 M | 9.01 M | 8.58 M | - | 6.08 M | 6.6 M | 5.54 M | - | 5.49 M | 5.34 M | 5.25 M | - | 4.17 M | 3.7 M | 3.34 M | - | 2.88 M | 2.39 M | 1.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
38.5 M | 36.5 M | - | 32.4 M | 32.3 M | 27.6 M | - | 28.1 M | 24.2 M | 19.4 M | - | 18.6 M | 19.9 M | 16.5 M | 15.9 M | 14.6 M | 9.76 M | 13.7 M | 13.9 M | 12.9 M | 11.2 M | 9.43 M | 7.8 M | 6.73 M | 5.38 M | 3.77 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-17.2 M | -14.9 M | - | -13.7 M | -14.3 M | -16.9 M | - | -9.23 M | -14.2 M | -16 M | - | -13.3 M | -9.95 M | -10.2 M | - | -9.33 M | -9.39 M | -9.14 M | - | -7.4 M | -6.02 M | -7.15 M | - | -4.68 M | -4.77 M | -4.65 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
1.72 M | 1.72 M | - | 1.73 M | 1.71 M | 1.69 M | - | 1.71 M | 1.03 M | 621 K | - | 633 K | 628 K | 623 K | - | 1.22 M | 1.2 M | 1.2 M | - | 1.18 M | 1.21 M | 1.35 M | - | 1.06 M | 1.01 M | 989 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-17.2 M | -14.9 M | - | -13.7 M | -14.3 M | -16.9 M | - | -9.23 M | -14.2 M | -16 M | - | -13.3 M | -9.95 M | -10.2 M | - | -9.33 M | -9.02 M | -8.96 M | - | -6.86 M | -5.67 M | -6.97 M | - | -4.36 M | -4.64 M | -4.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
55.7 M | 51.4 M | - | 46.1 M | 46.6 M | 44.5 M | - | 37.3 M | 38.4 M | 35.4 M | - | 31.9 M | 29.8 M | 26.7 M | - | 23.9 M | 19.2 M | 22.8 M | - | 20.3 M | 17.2 M | 16.6 M | - | 11.4 M | 10.1 M | 8.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
43.8 M | 40.8 M | - | 36 M | 35.8 M | 34.1 M | - | 28.8 M | 27.7 M | 27.3 M | - | 25 M | 22.5 M | 21.2 M | - | 19.2 M | 15.8 M | 19.7 M | - | 17.1 M | 14.1 M | 13.9 M | - | 8.97 M | 7.82 M | 6.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Silk Road Medical, Inc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Conformis
CFMS
|
- | - | $ 16.4 M |  USA |
 |
Bruker Corporation
BRKR
|
$ 64.0 | 7.26 % | $ 9.72 B | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 0.06 % | $ 66.1 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.7 | 0.06 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.61 | 13.03 % | $ 414 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.18 | 3.31 % | $ 1.4 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.3 | 1.63 % | $ 268 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
$ 16.08 | 0.75 % | $ 576 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
$ 27.86 | 1.05 % | $ 230 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 65.58 | 3.69 % | $ 1.94 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 85.73 | 0.32 % | $ 50.1 B | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
AdaptHealth Corp.
AHCO
|
$ 5.57 | 0.43 % | $ 753 M | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.9 | 0.69 % | $ 63.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.88 | 2.25 % | $ 1.22 B | USA |
 |
Inogen
INGN
|
$ 5.23 | 2.75 % | $ 139 M | USA |
 |
InMode Ltd.
INMD
|
$ 14.19 | 0.21 % | $ 917 M | Israel |
 |
Inspire Medical Systems
INSP
|
$ 68.81 | 0.59 % | $ 2.02 B | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 2.51 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 85.2 | 0.08 % | $ 1.08 B | USA |
 |
AxoGen
AXGN
|
$ 43.32 | 0.48 % | $ 1.99 B | USA |
 |
Align Technology
ALGN
|
$ 145.63 | 4.36 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
$ 7.08 | 0.28 % | $ 84.7 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Medtronic PLC
MDT
|
$ 88.51 | 0.32 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.71 | 0.1 % | $ 696 M | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
$ 1.67 | 1.83 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.66 | 0.45 % | $ 42.8 M | Israel |
 |
InspireMD
NSPR
|
$ 0.7 | 0.37 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.16 | 0.11 % | $ 363 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.13 | 1.29 % | $ 47.6 K | USA |
 |
Insulet Corporation
PODD
|
$ 135.78 | 0.01 % | $ 9.55 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.6 | 1.66 % | $ 169 M | Canada |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.18 | 0.63 % | $ 136 M | USA |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |
 |
AVITA Medical
RCEL
|
$ 11.58 | 5.75 % | $ 323 M |  Australia |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.83 | 1.37 % | $ 116 M | USA |
 |
Sintx Technologies
SINT
|
$ 1.87 | 5.06 % | $ 5.19 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.22 | 0.4 % | $ 27 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.68 | 0.02 % | $ 23.1 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |